Chinese General Practice ›› 2018, Vol. 21 ›› Issue (27): 3397-3402.DOI: 10.3969/j.issn.1007-9572.2018.00.232
• Monographic Research • Previous Articles Next Articles
Published:
2018-09-20
Online:
2018-09-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.3969/j.issn.1007-9572.2018.00.232
[1]BROWNING J D,SZCZEPANIAK L S,DOBBINS R,et al.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J].Hepatology,2004,40(6):1387-1395.DOI:10.1002/hep.20466.3400 [2]VERNON G,BARANOVA A,YOUNOSSI Z M.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.DOI:10.1111/j.1365-2036.2011.04724.x.3400 [3]CLEMENTE M G,MANDATO C,POETA M,et al.Pediatric non-alcoholic fatty liver disease:recent solutions,unresolved issues,and future research directions[J].World J Gastroenterol,2016,22(36):8078-8093.DOI:10.3748/wjg.v22.i36.8078.3401 [4]LU Z Y,SHAO Z,LI Y L,et al.Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population:an 8-year follow-up study[J].World J Gastroenterol,2016,22(13):3663-3669.3401 [5]CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J].Gastroenterology,2012,142(7):1592-1609.DOI:10.1053/j.gastro.2012.04.001.3401 [6]WONG R J,CHEUNG R,AHMED A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.[J].Hepatology,2014,59(6):2188-2195.DOI:10.1002/hep.26986.3401 [7]KUSHIYAMA A,NAKATSU Y,MATSUNAGA Y,et al.Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis[J].Mediators Inflamm,2016,2016:8603164.DOI:10.1155/2016/8603164.3401 [8]SHARAF EL DIN UAA,SALEM M M,ABDULAZIM D O.Uric acid in the pathogenesis of metabolic,renal,and cardiovascular diseases:a review[J].J Adv Res,2017,8(5):537-548.DOI:10.1016/j.jare.2016.11.004.3401 [9]MAIUOLO J,OPPEDISANO F,GRATTERI S,et al.Regulation of uric acid metabolism and excretion[J].Int J Cardiol,2016,213:8-14.DOI:10.1016/j.ijcard.2015.08.109.3401 [10]KAMOGAWA E,SUEISHI Y.A multiple free-radical scavenging(MULTIS)study on the antioxidant capacity of a neuroprotective drug,edaravone as compared with uric acid,glutathione,and trolox[J].Bioorg Med Chem Lett,2014,24(5):1376-1379.DOI:10.1016/j.bmcl.2014.01.045.3401 [11]ASHTARI F,BAHAR M,AGHAEI M,et al.Serum uric acid level in patients with relapsing-remitting multiple sclerosis[J].J Clin Neurosci,2013,20(5):676-678.DOI:10.1016/j.jocn.2012.05.054.3401 [12]SAUTIN Y Y,NAKAGAWA T,ZHARIKOV S,et al.Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress[J].Am J Physiol Cell Physiol,2007,293(2):C584-596.DOI:10.1152/ajpcell.00600.2006.3401 [13]MARTYN K D,FREDERICK L M,VON LOEHNEYSEN K,et al.Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases[J].Cell Signal,2006,18(1):69-82.DOI:10.1016/j.cellsig.2005.03.023.3401 [14]张涛,迟雁青,杜春阳,等.尿酸对人肾小管上皮细胞氧化应激和TGF-β表达的影响[J].免疫学杂志,2014,30(7):585-589.DOI:10.13431/j.cnki.immunol.j.20140128.3401 ZHANG T,CHI Y Q,DU C Y,et al.Effects of uric acid on oxidative stress and TGF-β expression of human renal tubular epithelia cell[J].Immunological Journal,2014,30(7):585-589.DOI:10.13431/j.cnki.immunol.j.20140128.3401 [15]LIU C Q,HE C M,CHEN N,et al.Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults[J].Sci Rep,2016,6:38605.DOI:10.1038/srep38605.3401 [16]LIN H,LI Q,LIU X,et al.Liver fat content is associated with elevated serum uric acid in the Chinese middle-aged and elderly populations:Shanghai Changfeng Study[J].PLoS One,2015,10(10):e0140379.DOI:10.1371/journal.pone.0140379.3401 [17]LIU Z,QUE S,ZHOU L,et al.Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence:a meta-analysis of prospective studies[J].Sci Rep,2015,5:14325.DOI:10.1038/srep14325.3401 [18]YU T Y,JEE J H,BAE J C,et al.Serum uric acid:a strong and independent predictor of metabolic syndrome after adjusting for body composition[J].Metabolism,2016,65(4):432-440.DOI:10.1016/j.metabol.2015.11.003.3401 [19]CAI W,SONG J M,ZHANG B,et al.The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population[J].Scientific World Journal,2014,2014:393628.DOI:10.1155/2014/393628.3401 [20]HUANG Q,YU J,ZHANG X,et al.Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease[J].Biomed Rep,2016,5(2):188-192.DOI:10.3892/br.2016.698.3401 [21]WU S J,ZHU G Q,YE B Z,et al.Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults:a large population-based study[J].Medicine(Baltimore),2015,94(17):e802.DOI:10.1097/MD.0000000000000802.3401 [22]WAN X,XU C,LIN Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.DOI:10.1016/j.jhep.2015.11.022.3401 [23]LOMBARDI R,PISANO G,FARGION S.Role of serum uric acid and ferritin in the development and progression of NAFLD[J].Int J Mol Sci,2016,17(4):548.DOI:10.3390/ijms17040548.3401 [24]LI C,HSIEH M C,CHANG S J.Metabolic syndrome,diabetes,and hyperuricemia[J].Curr Opin Rheumatol,2013,25(2):210-216.DOI:10.1097/BOR.0b013e32835d951e.3401 [25]VACCA M,ALLISON M,GRIFFIN J L,et al.Fatty acid and glucose sensors in hepatic lipid metabolism:implications in NAFLD[J].Semin Liver Dis,2015,35(3):250-261.DOI:10.1055/s-0035-1562945.3401 [26]ZHI L,YUZHANG Z,TIANLIANG H,et al.High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo[J].PLoS One,2016,11(2):e0147737.DOI:10.1371/journal.pone.0147737.3401 [40]GOPAL K,JOHNSON T C,GOPAL S,et al.Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment[J].Hepatology,2006,44(2):335-340.DOI:10.1002/hep.21261.3402 [41]GIRELLI D,PASINO M,GOODNOUGH J B,et al.Reduced serum hepcidin levels in patients with chronic hepatitis C[J].J Hepatol,2009,51(5):845-852.DOI:10.1016/j.jhep.2009.06.027.3402 [42]GOPAL K,JOHNSON T C,GOPAL S,et al.Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment[J].Hepatology,2006,44(2):335-340.DOI:10.1002/hep.21261.3402 [43]BODLAJ G,HUBMANN R,SALEH K,et al.Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response[J].World J Gastroenterol,2010,16(19):2407-2410.DOI:10.3748/wjg.v16.i19.2407.3402 [44]EZZIKOURI S,KIMURA K,SUNAGOZAKA H,et al.Serum DHCR24 auto-antibody as a new biomarker for progression of hepatitis C[J].EBioMedicine,2015,2(6):604-612.DOI:10.1016/j.ebiom.2015.04.007.3402 [45]SAITO M,YANO Y,HIRANO H,et al.Serum NX-DCP as a new noninvasive model to predict significant liver fibrosis in chronic hepatitis C[J].Hepat Mon,2015,15(2):e22978.DOI:10.5812/hepatmon.22978.3402 [27]AVULA N R,SHENOY D.Evaluation of association of hyperuricaemia with metabolic syndrome and insulin resistance[J].J Clin Diagn Res,2016,10(12):OC32-34.DOI:10.7860/JCDR/2016/22182.9113.3402 [28]TAKIR M,KOSTEK O,OZKOK A,et al.Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia[J].J Investig Med,2015,63(8):924-929.DOI:10.1097/JIM.0000000000000242.3402 [29]LANASPA M A,SANCHEZ-LOZADA L G,CHOI Y J,et al.Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress:potential role in fructose-dependent and -independent fatty liver[J].J Biol Chem,2012,287(48):40732-40744.DOI:10.1074/jbc.M112.399899.3402 [30]CHOI Y J,SHIN H S,CHOI H S,et al.Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes[J].Lab Invest,2014,94(10):1114-1125.DOI:10.1038/labinvest.2014.98.3402 [31]SOZEN E,OZER N K.Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases:an updated mini-review[J].Redox Biol,2017,12:456-461.DOI:10.1016/j.redox.2017.02.025.3402 [32]DE TORRE-MINGUELA C,MESA DEL CASTILLO P,PELEGRN P.The NLRP3 and pyrin inflammasomes:implications in the pathophysiology of autoinflammatory diseases[J].Front Immunol,2017,8:43.DOI:10.3389/fimmu.2017.00043.3402 [33]CAI C,ZHU X,LI P,et al.NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid[J].Inflammation,2017,40(6):1875-1883.DOI:10.1007/s10753-017-0628-z.3402 [34]WAN X,XU C,LIN Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.DOI:10.1016/j.jhep.2015.11.022.3402 [35]RONCAL-JIMENEZ C A,LANASPA M A,RIVARD C J,et al.Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake[J].Metabolism,2011,60(9):1259-1270.DOI:10.1016/j.metabol.2011.01.008.3402 [36]JOHNSON R J,NAKAGAWA T,SANCHEZ-LOZADA L G,et al.Sugar,uric acid,and the etiology of diabetes and obesity[J].Diabetes,2013,62(10):3307-3315.DOI:10.2337/db12-1814.3402 [37]ISHIMOTO T,LANASPA M A,LE M T,et al.Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice[J].Proc Natl Acad Sci U S A,2012,109(11):4320-4325.DOI:10.1073/pnas.1119908109.3402 [38]LANASPA M A,SANCHEZ-LOZADA L G,CICERCHI C,et al.Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver[J].PLoS One,2012,7(10):e47948.DOI:10.1371/journal.pone.0047948.3402 [39]旷历琼,王娜.中老年非酒精性脂肪肝患者临床特点及其与血脂、血尿酸水平的相关性分析[J].疑难病杂志,2014,13(10):1012-1014.DOI:10.3969/j.issn.1671-6450.2014.10.08.3402 KUANG L Q,WANG N.The characters of nonalcoholic fatty liver disease and the related risk factors with blood lipid and serum uric acid[J].Chinese Journal of Difficult and Complicated Cases,2014,13(10):1012-1014.DOI:10.3969/j.issn.1671-6450.2014.10.08.3402 [40]高锦凤,宋镇,何方平,等.非酒精性脂肪性肝病与尿酸水平和肾功能损伤的相关性研究[J].疑难病杂志,2010,9(7):518-520.DOI:10.3969/j.issn.1671-6450.2010.07.018.3402 GAO J F,SONG Z,HE F P,et al.Relationship between uric acid level and renal function impairment in nonalcoholic fatty liver disease[J].Chinese Journal of Difficult and Complicated Cases,2010,9 (7):518-520.DOI:10.3969/j.issn.1671-6450.2010.07.018.3402 |
[1] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[2] | BAI Yitong, LIN Lianjie, PEI Dongmei. Correlation between the Severity of Metabolic-associated Fatty Liver Disease and Thyroid Nodules [J]. Chinese General Practice, 2023, 26(27): 3392-3396. |
[3] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[4] | FENG Xiaoling, YIN Wenqing, WANG Ying, HOU Lihui. Correlation Analysis between Different Free Testosterone Index Levels and Clinical Characteristics of Patients with Polycystic Ovary Syndrome [J]. Chinese General Practice, 2023, 26(24): 3005-3009. |
[5] | GAO Zhe, DUAN Kaixin, LYU Xiuqin, MA Huijuan, ZHANG Zhimei, SONG Guangyao. Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet [J]. Chinese General Practice, 2023, 26(21): 2639-2646. |
[6] | ZHANG Zhuoran, YU Changhe, AN Yi, HE Xin, GUO Yi, DENG Jinyan, LI Yue, HAN Deng, PI Shanshan, HE Junzhi, CHEN Yue, YE Yong'an, DU Hongbo. Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study [J]. Chinese General Practice, 2023, 26(20): 2439-2446. |
[7] | XIN Jiadong, ZHOU Jiabao, WU Zhiyuan, ZHANG Xuming, GAO Jiandong. Advances in Urate Excretion and Urate Transporters in Hyperuricemia [J]. Chinese General Practice, 2023, 26(15): 1916-1922. |
[8] | SONG Hualong, GAO Ying. Association between Serum Uric Acid and the Risk of Type 2 Diabetes Mellitus: a Population-based Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(15): 1831-1839. |
[9] | WANG Junwei, LIN Lingjun, SONG Linling, CHENG Xiaocui, NIE Xiuling. Association between Serum Potassium and Metabolic-associated Fatty Liver Disease in Patients with Primary Gout [J]. Chinese General Practice, 2023, 26(12): 1479-1484. |
[10] | QIAN Fangfang, CAI Zhensheng, GU Tian, LI Haoxiang, ZHAO Li, YANG Ling, DENG Xia, YUAN Guoyue. Relationship between Ectodysplasin A and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(08): 911-916. |
[11] | FU Weiqiang, ZHOU Jianbo, WU Xiongjian, HUANG Caibin. Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota [J]. Chinese General Practice, 2023, 26(06): 742-748. |
[12] | WANG Yingjie, CHENG Haoran, ZHOU Weihong. Correlation of Body Fat Composition and Metabolic Indicators with Metabolic-associated Fatty Liver Disease in a Non-obese Population [J]. Chinese General Practice, 2023, 26(06): 672-680. |
[13] | SHI Xuexiu, YUN Wenjing, WANG Haixu, ZHAO Yingying, YANG Yanan, SUN Tongwen. Clinical Features of Hepatic Cirrhosis in Hypopituitarism [J]. Chinese General Practice, 2023, 26(06): 699-703. |
[14] | YAO Huihui, SHU Lin, YAO Linli, LI Sha, YANG Xiaotong, LI Yunchun. Sex-specific Analysis of Influencing Factors for the Association between Baseline Serum Uric Acid and Two-year Outcome after First Acute Ischemic Stroke [J]. Chinese General Practice, 2023, 26(05): 557-562. |
[15] | Fangyuan CONG, Qian XUE, Lihua DENG, Luying ZHU, Jingtong WANG. Correlation between Nonalcoholic Fatty Liver Disease and Early Left Ventricular Diastolic Dysfunction [J]. Chinese General Practice, 2022, 25(26): 3290-3297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||